Noncontrolling Interest (Tables)

9 Months Ended

Sep. 30, 2022

Noncontrolling Interest [Abstract]

Schedule of Noncontrolling Interest of Stockholders' Equity

The noncontrolling interest (“NCI”) included as a component of consolidated total stockholders’ equity is summarized for the periods indicated as follows:

	September 30, 2022			December 31, 2021
NCI – equity (deficit) – beginning of period	$	17,752		$	(2,369	)
Investment in Veris Health Inc.		—			6
Net loss attributable to NCI – Lucid Diagnostics Inc.		(9,032	)		(5,779	)
Net loss attributable to NCI – Solys Diagnostics Inc.		(6	)		—
Net loss attributable to NCI – Veris Health Inc.		(1,105	)		—
Impact of subsidiary equity transactions		(1,375	)		16,760
Lucid Diagnostics Inc. proceeds from Committed Equity Facility, net of deferred financing charges		1,767			—
Lucid Diagnostics Inc. issuance of common stock for settlement of APA-RDx installment payment		427			—
Lucid Diagnostics Inc. 2018 Equity Plan stock option exercise		694			—
Lucid Diagnostics Inc. Employee Stock Purchase Plan Purchase		109			—
Stock-based compensation expense - Lucid Diagnostics Inc. 2018 Equity Plan		10,371			9,134
Stock-based compensation expense - Veris Health Inc. 2021 Equity Plan		6			—
NCI – equity (deficit) – end of period	$	19,608		$	17,752